Finnhub · May 6, 2026
CytoMed Therapeutics : Audited Financial Statements for FY2025
CYTOMED THERAPEUTICS LIMITED AND ITS SUBSIDIARIES Directors' Statement and Financial Statements for the financial year ended 31 December 2025 ...
GD
NASDAQ · GDTC
CytoMed Therapeutics Limited
Healthcare · Biotechnology
$1.03
Up+$0.13 (+14.57%)
Updated Aug 24, 2026, 1:35 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 19.36M
- P/E ratio
- -5.82
- Dividend yield
- 0.00%
- 52-week range
- $0.68 – $1.39
- Volume
- 60.31K
- Avg. volume
- 120.59K
Price performance
GDTC price history
1M range · 20 trading sessions · Daily adjusted prices
GDTC closed at $1.03 after 20 trading sessions, up 14.47% for the selected period.
- Last close
- $1.03
- Period change
- +14.47%
- Period low
- $0.80
- Period high
- $1.03
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $0.8025 | $1.0301 | $0.8025 | $1.03 | 60.31K |
| Aug 20, 2026 | $0.89 | $0.899 | $0.86 | $0.899 | 5.41K |
| Aug 19, 2026 | $0.9799 | $0.9799 | $0.89 | $0.90 | 16.98K |
| Aug 18, 2026 | $0.8976 | $0.9596 | $0.8976 | $0.9396 | 4K |
| Aug 17, 2026 | $0.912 | $0.98 | $0.88 | $0.9058 | 24.48K |
| Aug 14, 2026 | $0.851 | $0.949 | $0.80 | $0.9489 | 30.46K |
| Aug 13, 2026 | $0.8001 | $0.845 | $0.80 | $0.845 | 27.84K |
| Aug 12, 2026 | $0.8428 | $0.859 | $0.7773 | $0.8085 | 14.67K |
| Aug 11, 2026 | $0.8101 | $0.8428 | $0.80 | $0.8428 | 2.74K |
| Aug 10, 2026 | $0.8201 | $0.893 | $0.80 | $0.8001 | 50.5K |
| Aug 7, 2026 | $0.875 | $0.875 | $0.8213 | $0.8213 | 3.79K |
| Aug 6, 2026 | $0.89 | $0.93 | $0.8029 | $0.8029 | 125.9K |
| Aug 5, 2026 | $0.84 | $0.95 | $0.8316 | $0.84 | 30.22K |
| Aug 4, 2026 | $0.892 | $0.892 | $0.80 | $0.8521 | 12.19K |
| Aug 3, 2026 | $0.92 | $0.96 | $0.8787 | $0.9192 | 6.36K |
| Jul 31, 2026 | $0.95 | $0.98 | $0.93 | $0.9301 | 26.74K |
| Jul 30, 2026 | $0.91 | $0.9894 | $0.91 | $0.9894 | 9.49K |
| Jul 29, 2026 | $0.879 | $0.9986 | $0.8706 | $0.91 | 18.93K |
| Jul 28, 2026 | $0.8998 | $1.15 | $0.7103 | $0.9051 | 443.76K |
| Jul 27, 2026 | $0.948 | $0.948 | $0.82 | $0.8998 | 189.25K |
Latest GDTC news
The latest Smart Investors Daily articles mentioning GDTC.
Stock researchCompany · Overview
GDTC research
Overview
Company profile and research snapshot.
Company profile
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 10, 2024 | Benchmark | Speculative Buy | — |
| Jun 11, 2024 | Benchmark | Speculative Buy | — |
| Dec 4, 2023 | Benchmark | Speculative Buy | — |
| Jul 21, 2023 | Benchmark | Speculative Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jan 28, 2026
CytoMed Therapeutics Refutes Recent Statements Regarding Inaccurate, Misleading Claims About Company's Research Programs, Clinical Progress, And Operations
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable
Yahoo · Jan 13, 2026
CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to update shareholders as we enter a new exciting year in 2026. As mentioned in previous announcements,
defenseworld.net · Dec 12, 2025
CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 7.2% – Here’s Why
CytoMed Therapeutics Limited (NASDAQ: GDTC - Get Free Report)'s stock price was up 7.2% on Thursday. The stock traded as high as $1.67 and last traded at $1.67. Approximately 32,493 shares traded hands during mid-day trading, a decline of 59% from the average daily volume of 78,542 shares. The stock had previously closed at $1.5573.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
